CXCR2 and colorectal carcinoma: Two small molecule CXCR2 antagonists, SCH-527123 and SCH-479833, were reported to be robust antimetastatic therapeutics in human CRC liver metastasis, which acts at the metastatic site by declining the tumor vascularization and enhancing the malignant cell apoptosis [158].